Quest Diagnostics stock trades near 52-week high on new kidney testing deal

Quest Diagnostics stock is holding close to its 52-week high as investors react to a new multi-year collaboration on kidney disease testing and a solid Moderate Buy analyst consensus.

Quest Diagnostics (ISIN US74834L1008) stock closed at 240.30 USD on August 31, 2026 on the New York Stock Exchange, keeping the diagnostics provider within sight of its 52-week high of 247.19 USD cited in recent insider-trading disclosures. As of September 1, 2026, the market is digesting a fresh multi-year collaboration that expands kidney disease testing across the United States.

Kidney testing collaboration adds strategic volume

A new multi-year agreement between Renalytix and Quest Diagnostics aims to make KidneyintelX.dkd blood testing broadly available to physicians and patients served by Quest in the United States, as announced on September 1, 2026. According to the Renalytix company statement, Quest will provide laboratory services and logistics to support KidneyintelX.dkd testing, with the goal of improving risk stratification for patients with diabetic kidney disease.

The deal positions Quest Diagnostics to capture additional test volume in kidney disease, a segment where chronic conditions drive recurring diagnostics demand. For investors, the agreement adds a tangible growth lever alongside the company’s existing investments in neurology and oncology testing, even though specific revenue targets were not disclosed. The partnership also underlines Quest’s role as a preferred national laboratory partner for specialized diagnostics innovators.

Analyst view and stock performance context

Quest Diagnostics stock performance remains robust in late August 2026. A price snapshot compiled from market data shows the shares closing at 240.30 USD on August 31, 2026, down 1.01 percent on the day but still up 38.48 percent year to date, according to quote data for ticker DGX. This places the stock close to the 52-week high of 247.19 USD referenced in an insider transaction report where an executive sold shares around 242.27 to 245.25 USD per share, illustrating how much the stock has appreciated over the past twelve months.

Institutional investors have been adding to positions in Quest Diagnostics in recent weeks. One portfolio overview notes that the average analyst rating on Quest Diagnostics is Moderate Buy, with a consensus price target of 235.31 USD, as reported by MarketBeat consensus figures. The current closing price of 240.30 USD therefore sits about 2.1 percent above this average target, signaling that the market already prices in a sizeable portion of the expected fundamental strength.

Dividend stability and recent Alzheimer testing expansion

Beyond price performance, Quest Diagnostics continues to underline its shareholder-return profile. In mid August 2026, the company reaffirmed a quarterly dividend of 0.86 USD per share, payable on October 21, 2026 to shareholders of record on October 6, 2026, according to a dividend notice summarized by a recent stock portal overview. At the August 31, 2026 closing price of 240.30 USD, this dividend level implies an annualized dividend of 3.44 USD per share and a dividend yield in the vicinity of 1.4 percent, showing that Quest pairs growth initiatives with ongoing cash returns to shareholders.

Operationally, Quest Diagnostics has also broadened its neurology portfolio. In late August 2026, coverage summaries point out that Quest added the Roche Elecsys pTau217 assay, cleared by the United States Food and Drug Administration, to its Alzheimer’s biomarker offering and launched a new multi biomarker blood test under the AD Detect label. While detailed revenue numbers for these launches will only become visible in the next quarterly report, the expansions suggest that Quest is positioning itself aggressively in neurodegenerative-disease diagnostics, a field with both clinical need and reimbursement potential.

Diagnostics portfolio: kidney, neurology and digital health

The collaboration around KidneyintelX.dkd strengthens Quest Diagnostics’ kidney-disease portfolio, complementing its core offering of routine laboratory testing. KidneyintelX.dkd is designed to combine blood biomarkers and clinical data to categorize diabetic kidney disease risk, and Quest’s national laboratory infrastructure should enable broad rollout across primary-care and specialist practices. For practitioners, having access to a standardized risk score via Quest’s network can help prioritize patients for nephrology referral and early intervention.

Quest’s broader product suite now also includes advanced neurology tests, such as the recently added FDA-cleared Roche Elecsys pTau217 assay for Alzheimer’s disease and the AD Detect multi biomarker blood test. These products expand Quest’s presence in brain-health diagnostics, targeting patients at risk of Alzheimer’s who may benefit from early detection or monitoring. The combination of kidney and neurology partnerships illustrates how Quest is using external innovation to enhance its specialty testing without shouldering all the discovery risk in-house.

Stock level and investor takeaway

From a pure stock perspective, Quest Diagnostics shares are trading above the average analyst target but still below the recently cited 52-week high. With a closing price of 240.30 USD on August 31, 2026 and a 52-week high of 247.19 USD, the gap to the top of the range is less than 3 percent, underlining how strongly the stock has performed over the year. The year-to-date gain of 38.48 percent, combined with a stable dividend of 0.86 USD per quarter and new specialty-testing collaborations, helps explain why institutional investors have been willing to accumulate the shares despite the valuation premium over consensus.

Quest Diagnostics stock facts

• Company: Quest Diagnostics Incorporated
• ISIN: US74834L1008
• Ticker: DGX
• Trading venue: NYSE
• Price (as of August 31, 2026, 16:00): 240.30 USD
• Market capitalization: 26,000,000,000 USD (as of August 31, 2026)
• Sector / Industry: Health Care / Diagnostics & Research
• Index membership: S&P 500